EGF ELISA Kit

Catalog No. ABIN577070

This Colorimetric ELISA kit is designed for the quantitative measurement of Human EGF.

Quick Overview for EGF ELISA Kit (ABIN577070)

Target: EGF (Epidermal Growth Factor (EGF))

Reactivity: Human

Detection Method: Colorimetric

Method Type: Sandwich ELISA

Detection Range: 20-1000 pg/mL

Application: ELISA

Product Details EGF ELISA Kit

Minimum Detection Limit: 20 pg/mL

Purpose: This EGF enzyme-linked immunosorbent assay (ELISA) applies a technique called a quantitative sandwich immunoassay. The microtiter plate provided in this kit has been pre- coated with a monoclonal specific for EGF. Standards or samples are then added - the appropriate microtiter plate wells and incubated. EGF if present, will bind and become immobilized by the antibody pre-coated on the wells. The microtiter plate wells are thoroughly washed - remove unbound EGF and other components of sample. In order - quantitate the amount of EGF present in the sample, a standardized preparation of horseradish peroxidase (HRP)-conjugated polyclonal antibody specific for EGF is added - each well to

Analytical Method: Quantitative

Sensitivity: < 20 pg/mL

Components: Standards: 1 set/2 vials

Application Details

Plate: Pre-coated

Restrictions: For Research Use only

Handling

Preservative: Without preservative

Target Details for EGF

Target: EGF (Epidermal Growth Factor (EGF))

Background: Hepatitis resulting from infection with viruses other than Hepatitis A Virus (HAV) and Hepatitis B (HBV) virus was previously referred to as non-A, non-B hepatitis. The first characterised non-A, non-B hepatitis agent was that responsible for parentally transmitted non-A, non-B hepatitis, or what is now called Hepatitis C Virus. This was followed by the cloning of a portion of the fecal-orally-transmitted agent, the Hepatitis E Virus (HEV). Hepatitis E Virus has been referred to as enterically transmitted non-A, non-B hepatitis. Epidemics of enterically transmitted Hepatitis E Virus have been recognised worldwide but occur principally in developing countries. They have been reported in Southeast Asia, central Asia, Africa, Mexico, and Central America. In these areas, contaminated water has been implicated as the principal vehicle of virus transmission. Increasingly, hepatitis E is found in developed countries. Domestic animals have been reported as a reservoir for this virus. HEV infection in most cases is self-limiting and could be asymptomatic sometimes. Although HEV and HAV are transmitted in a similar manner, there are major differences in the clinical, pathological, and epidemiological courses of these two viruses. In particular, the mortality rate for HEV infection is 1 to 2%, or approximately 1-fold greater than that seen for HAV. Infection with HEV is particularly fatal for pregnant women, for whom the mortality rate can be as high as 1 to 2%. This HEV Antibody ELISA is an immunoassay, which employs synthetic and recombinant HEV antigens, for the detection of antibodies to HEV in human serum or plasma. These antigens, which correspond to the structure regions of HEV, constitute the solid phase antigenic adsorbent that binds to antibodies that recognises the viral antigen. The detection of anti-HEV IgG in human blood indicates current viral infection or previous expose to this virus. Samples with O.D. values greater than or equal to the Cut-off value are defined as initially reactive. Initially reactive specimens are to be re-tested in duplicate. Samples, which do not react in either of the duplicate, are considered non-reactive for antibodies to HEV. Samples, which are reactive in either of the duplicates tests, are considered repeatedly reactive. S7.5(4) HEV IgG

Pathways: NF-kappaB Signaling, RTK Signaling, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway, Regulation of Carbohydrate Metabolic Process, Hepatitis C, Protein targeting to Nucleus, Interaction of EGFR with phospholipase C-gamma, Thromboxane A2 Receptor Signaling, EGFR Downregulation